1. Generics Bulletin

California Snaps Up Civica For Biosimilar Insulin Initiative

Plus Brand Insulins Drop Prices Following Landmark Lilly Decision

 
• By Chloe Kent

Civica is set to provide biosimilar insulins to the state of California through its CalRx program, following approval from the US Food and Drug Administration.

Gavin Newsom announces CalRx's contract with Civica
Governor Newsom says California will now pursue manufacturing its own naloxone • Source: Gavin Newsom

California has selected Civica as its insulin manufacturing partner, with the company now set to manufacture insulins for the state’s CalRx Biosimilar Insulin Initiative. CalRx will work with Civica to provide the most-used short- and long-acting insulins at planned prices of no more than $30 per 10ml vial and $55 for a box of five 3ml pre-filled pens.

Civica’s candidates are currently awaiting approval from the US Food and Drug Administration and are expected to reach the market in 2024

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.